DDI/DDC drugs comparative trial

National Institute of Allergy and Infectious Disease will begin a comparative trial of Bristol-Myers Squib's DDI and Hoffmann-LaRoche's DDC at 18 centers as part of the Community Programs for Clinical Research on AIDS Program. The two-year study will compare disease progression, frequency and severity of side effects, and effects on CD4 counts in 400 HIV-infected patients aged 13 years or older who have previously received AZT, have a T4 cell count of 300 or less, are receiving prophylaxis against Pneumocystis carinii pneumonia, or have an AIDS-defining illness. Patients will be accrued over one year then followed in regular clinical visits for another year.